ClinicalTrials.gg
WithdrawnNCT00202891Updated Jun 3, 2015

Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)

A Phase 4 interventional study of sisomicin in Pyoderma, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2015-06-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Why this study was withdrawn
No further local interest in pursuing the study.
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Study summary

This open-label, randomized, parallel-group clinical study is designed to compare the efficacy and safety of the topical antibiotic, sisomicin cream, with that of another topical antibiotic cream, nadifloxacin cream, in the treatment of Indian patients with primary pyodermas.

02

Conditions studied

  • Pyoderma

Browse trials for

Keywords

  • pyoderma
  • sisomicin
  • nadifloxacin
03

In context

Pyoderma

11 studies on the registry are indexed under Pyoderma; 2 are open to participants now.

Browse Pyoderma studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,166 studies on the registry; 132 are open to participants now.

Of its 501 completed or terminated interventional studies of FDA-regulated products, 370 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either sex and suffering from primary pyodermas requiring topical antibiotic therapy without occlusive dressings.
  • >=6 years of age.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Patients must not take any other antibiotics.
  • Patients should not be hypersensitive to any of the test drugs.
  • Patients are not to have any other drug within one month of starting this study.
  • Patients cannot be enrolled more than once in the study.
  • Patients must not have any significant medical condition which, in the judgment of the investigator, might interfere with the study or require treatment.
  • Pregnant women and nursing mothers are to be excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Interventions

  • Drugsisomicin
06

Study locations

No study locations are listed for this record.

07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2005
First posted
Sep 20, 2005
Start
May 2007
CompletionActual
Sep 2007
Last update
Jun 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00202891
Collaborators
Fulford India Limited
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
May 2007
Completion
Sep 2007
Last update
Jun 3, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion